Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E17.92 EPS (ttm)15.34 Insider Own0.10% Shs Outstand218.90M Perf Week-2.73%
Market Cap60.20B Forward P/E13.68 EPS next Y20.10 Insider Trans-1.56% Shs Float218.79M Perf Month5.64%
Income3.55B PEG1.90 EPS next Q4.66 Inst Own89.10% Short Float1.15% Perf Quarter0.71%
Sales10.76B P/S5.59 EPS this Y24.00% Inst Trans0.04% Short Ratio1.39 Perf Half Y-6.37%
Book/sh47.18 P/B5.83 EPS next Y6.85% ROA19.00% Target Price345.67 Perf Year-26.46%
Cash/sh16.38 P/C16.79 EPS next 5Y9.45% ROE34.50% 52W Range242.07 - 420.99 Perf YTD-10.24%
Dividend- P/FCF18.38 EPS past 5Y31.30% ROI23.50% 52W High-34.68% Beta0.84
Dividend %- Quick Ratio2.20 Sales past 5Y17.90% Gross Margin88.50% 52W Low13.60% ATR6.90
Employees7350 Current Ratio2.60 Sales Q/Q6.70% Oper. Margin47.90% RSI (14)51.69 Volatility2.11% 2.55%
OptionableYes Debt/Eq0.63 EPS Q/Q26.80% Profit Margin34.30% Rel Volume1.07 Prev Close281.08
ShortableYes LT Debt/Eq0.63 EarningsApr 21 BMO Payout0.00% Avg Volume1.81M Price274.99
Recom2.10 SMA200.78% SMA503.98% SMA200-4.35% Volume1,939,172 Change-2.17%
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Apr-30-16 12:01AM  [$$] AmerisourceBergen Is No. 1 in Barron's 500 at
Apr-29-16 04:10PM  Apple Drives Selloff on April's Last Trading Day at TheStreet
02:42PM  Stocks Sell Off in Final Trading Day of April at TheStreet
01:14PM  What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead at Forbes
11:07AM  BIOGEN INC. Files SEC form 8-K, Other Events EDGAR Online
07:39AM  Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA (Daclizumab) for Treatment of Multiple Sclerosis Business Wire
07:26AM  Biogen, AbbVie multiple sclerosis drug wins EU green light Reuters
Apr-28-16 01:02PM  ETFs with exposure to Biogen, Inc. : April 28, 2016 at Capital Cube
12:00PM  Biotech Boom May Continue Through Earnings Season Benzinga
10:06AM  Tysabri Reports Strong Patient Growth in 1Q16 Market Realist
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Zacks
Apr-27-16 04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
01:04PM  BIOGEN INC. Financials EDGAR Online Financials
10:49AM  Why Biogen Is Poaching This Pfizer Exec to Head Up Its R&D Shop at Fortune
09:23AM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
09:15AM  Biogen Appoints Michael Ehlers Executive Vice President, Research and Development Business Wire
09:05AM  4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG Zacks
08:10AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Apr-26-16 12:07PM  Biogens Hemophilia Drugs Continue to Capture Market Share in 1Q16 Market Realist
11:40AM  Biogen Is Ready to Rise After a 10-Month Downward Spiral at TheStreet
Apr-25-16 11:57AM  Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16 Market Realist
11:56AM  How Did Biogen Perform in 1Q16? Market Realist
Apr-24-16 12:59PM  5 Trade Ideas for Monday: Biogen, KKR,, Zillow and ON Semi Yahoo Finance Contributors
Apr-22-16 06:17PM  Still The Greatest Growth Company Wall Street Has Never Heard Of Yahoo Finance Contributors
06:00PM  Biogen Inc Earnings Explode Higher, Revenue Not So Much at Motley Fool
12:57PM  Leerink Lowers Biogen Price Target Ahead Of M&A Potential at
12:06PM  Here Are the Fortune 500s Highest Paid Tech Execs at Fortune
Apr-21-16 05:25PM  [$$] Biogen: Biotech Bargain at +5.16%
12:57PM  Key Morning Earnings for April 21: BIIB, GM, UA, VZ Zacks
12:17PM  7 Stocks, 7 trades: YUM, GM, BIIB & more CNBC
12:04PM  Heres Why Biogens Shares Are Climbing Today at Fortune
11:55AM  Drop in Biogens research costs not a deliberate effort, says CEO at American City Business Journals
11:37AM  Edited Transcript of BIIB earnings conference call or presentation 21-Apr-16 12:30pm GMT Thomson Reuters StreetEvents
11:22AM  Cost cutting helps Biogen top Wall Street estimates for quarter Reuters
10:33AM  Biogen Q1 Earnings Beat Estimates, But Sales Miss; Stock Climbs at Investor's Business Daily
10:23AM  New Earnings, Same Old Biogen at
10:17AM  Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss Zacks
08:49AM  Biogen (BIIB) Beats on 1Q Earnings by a Wide Margin Zacks
07:49AM  Biogen beats 1Q profit forecasts AP
07:27AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
07:27AM  Biogen first-quarter sales rise 6.7 percent Reuters
07:15AM  Biogen Reports First Quarter 2016 Revenues of $2.7 Billion Business Wire
07:07AM  Q1 2016 Biogen Inc Earnings Release - Before Market Open CCBN
Apr-20-16 03:10PM  Why It May Be Time to Get Bullish on Biotech Yahoo Finance Contributors
12:29PM  Why Biotech Will Benefit from Higher Drug Prices at
10:10AM  Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money at TheStreet
07:30AM  Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action Business Wire
Apr-19-16 06:49PM  [$$] Biogen Earnings: What to Watch at The Wall Street Journal
12:54PM  Why Johnson & Johnson's Earnings are Good News for Big Biotech at
12:52PM  [Podcast] Biotech Analyst: Why revenue should be the focus for Q1 and how the upcoming election will impact names in the space
11:31AM  Wall Street is Dead Wrong: Why It's Time to Buy Illumina
10:00AM  How Will Drug Stocks BIIB, ABT, NVS Perform in Q1 Earnings?
Apr-18-16 02:51PM  Here Are All The Companies That Report Earnings This Week
08:18AM  Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?
07:30AM  TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness Business Wire
Apr-15-16 12:19PM  Biotech: Why Earnings Might Be Better Than You Think at
11:30AM  Biogen CEO nets $49 million in pay and stock gains in 2015 at
11:07AM  A Look at Ionis Pharmaceuticals Nusinersen
Apr-14-16 01:32PM  Gilead Sciences: Maybe It'll Beat After All? at
08:00AM  Biogen Joins in Celebration of World Hemophilia Day Business Wire
Apr-12-16 04:00PM  Generic Drug Helps Multiple Sclerosis Damage in Mid-Stage Trial at Bloomberg
11:51AM  Biotech: If M&A is the Answer, What's the Question? at
11:45AM  Cambridge biotech aims at a better way to test new drugs for ALS at
09:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
07:30AM  Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients Business Wire
Apr-11-16 11:43AM  Wait, I Thought Biogen Was Looking to Buy Stuff?!?! at
05:30AM  Politicians Impede Prosperity
Apr-09-16 12:06AM  What Are Incytes Revenue Streams?
Apr-08-16 02:53PM  Biogen explores sale of hemophilia assets -sources
11:42AM  [Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
09:08AM  How Could Baxalta Acquisition Become a Catalyst for Shire?
Apr-07-16 06:25PM  Allergan Struck a $3.3 Billion Alzheimers Drug Deal Right After Its Pfizer Merger Collapsed at Fortune
11:04AM  Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?
Apr-06-16 07:01PM  Cramer: See What Happens When Takeover Talk Gets Going? +5.25%
05:40PM  The Allergan 'Dating Game'
04:14PM  Jim Cramer: Biogen (BIIB) 'Does Not Fit the Allergan Bill' at TheStreet
02:08PM  Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data
11:06AM  Biotech M&A Will Flow From the Ashes of Scuttled Pfizer-Allergan Merger at TheStreet
10:05AM  5 Biotechs With the Most Upside This Earnings Cycle at 24/7 Wall St.
09:08AM  Regenerons Stock Reacts to Dupilumab Phase 3 Trials
07:40AM  Collapse of Pfizergan deal to revive talk of Biogen buyout at
Apr-05-16 07:04PM  Cramer: Hope for biotech in the blast zone at CNBC
06:00AM  Allergan Could Buy These Drug Companies if the Pfizer Merger Is Scuttled at TheStreet
Apr-04-16 08:44AM  Better Buy: Gilead Sciences Inc. vs. Biogen Inc. at Motley Fool
Apr-03-16 07:00PM  Samsung brings in the lawyers for biosimilars push
Apr-02-16 02:03PM  The Secrets Out: These Biotech Marvels Have Fallen Too Far
Apr-01-16 11:30AM  FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion Business Wire
08:08AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : April 1, 2016
Mar-30-16 04:00PM  Radius Health files for approval of osteoporosis drug to rival Forteo at
10:58AM  Can Biotechnology Company Biogen Beat the Industry's Patent Woes? at TheStreet
10:10AM  Stock Market News for March 30, 2016
08:25AM  Akamai, Cambridges hometown hero,' staying in Kendall Square at
08:00AM  Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer Business Wire
Mar-29-16 07:00AM  Healthcare: Drug Reform Worries Are Overblown at Morningstar
02:06AM  What Does Novartis Expect for Its Pharmaceuticals Segment in 1Q16?
Mar-28-16 04:09PM  Biogen (BIIB) Stock Price Target Cut at Leerink at TheStreet
04:01PM  Biogen to Present at the Goldman Sachs Alzheimers Symposium Business Wire
01:01PM  9 Things You Need to Know About Biosimilar Drugs at Motley Fool
08:56AM  This Biotech Has Gone from Wall St. Darling to Distressed Equity at TheStreet
05:30AM  Could the Fed Lose Credibility?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM